Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) PRKAG2 Antibodies:
anti-Human PRKAG2 Antibodies:
anti-Mouse (Murine) PRKAG2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal PRKAG2 Primary Antibody for ICC, IF - ABIN4347313
Martiáñez, Francès, López: Generation of digital responses in stress sensors. in The Journal of biological chemistry 2009
Show all 2 Pubmed References
the PRKAG2 gene can be used for marker-assisted selection to improve the body measurement and meat quality traits in the Qinchuan cattle population.
No differences in PRKAG2 transcript abundance were detected in small intestine, liver or muscle. Correlation between gene expression level of PRKAG2 in rumen and average daily feed intake was detected in both seasons but the direction differed by season.
Alleles of 2 equine AMPK (show PRKAA1 Antibodies) gamma subunit genes had no causative role in polysaccharide storage myopathy in horses
Identify a novel, de novo PRKAG2 mutation (K475E) in the cystathionine beta-synthase (show CBS Antibodies) 3 repeat, a region critical for AMP (show APRT Antibodies) binding, which affects AMP-activated protein kinase (show PRKAA2 Antibodies) activity, activates cell growth pathways, and results in cardiac hypertrophy, which can be reversed with rapamycin.
PRKAG2 polymorphism maybe important factor treating hypertensive patients with hydrochlorothiazide.
Data suggest different gamma-isoforms in AMPK (show PRKAA1 Antibodies) can have different effects on enzyme activation; here, activation of AMPK (show PRKAA1 Antibodies) by compound 991 is greater if AMPK (show PRKAA1 Antibodies) contains PRKAG2 versus PRKAG1 (show PRKAG1 Antibodies) or PRKAG3 (show PRKAG3 Antibodies).
mice with chronic AMPK (show PRKAA1 Antibodies) activation, resulting from mutation of the AMPK gamma2 subunit, exhibit ghrelin (show GHRL Antibodies) signaling-dependent hyperphagia, obesity, and impaired pancreatic islet insulin (show INS Antibodies) secretion. Humans bearing the homologous mutation manifest a congruent phenotype.
PRKAG2 cardiac syndrome may present with eccentric distribution of LVH, involving focal mid-infero-lateral pattern in the early disease stage, and more diffuse pattern but focusing on interventricular septum in advanced cases.
Overexpression of G100S mutation in PRKAG2 causes Wolff-Parkinson-White syndrome in transgenic zebrafish.
Its mutation causes AMPK (show PRKAA1 Antibodies) signaling abnormality which leads to cardiac syndrome.
The PRKAG2 autosomal dominant cardiac syndrome may be commonly characterized by Left Ventricular Hypertrophy, an accessory pathway, and progression to conduction disease requiring implantation of a pacemaker.
Data indicate that except AMPK (show PRKAA1 Antibodies)-alpha1, expressions of the other five AMPK (show PRKAA1 Antibodies) subunits -alpha2, -beta1, -beta2, -gamma1 and -gamma2 are significantly higher in ovarian carcinomas.
Single nucleotide polymorphisms in PRKAG2 is associated with drug response in breast cancer.
These results demonstrate that expression of AMPK subunit gamma-2(NI) and AMPK subunit gamma-2(RG) mutations at physiological levels can induce beneficial metabolic effects but that this is accompanied by Wolff-Parkinson-White Syndrome syndrome.
Prkag2 point mutation causes glycogen (show GYS1 Antibodies) storage via enhanced insulin (show INS Antibodies) sensitivity and AKT (show AKT1 Antibodies) activation. It stimulates postnatal cardiomyocyte proliferation by downregulating FoxO (show FOXO3 Antibodies). It promotes cardiac hypertrophy via mTOR (show FRAP1 Antibodies) activation in developed hearts.
We have demonstrated that a third AMPK gamma2 variant, gamma2-3B, is increasingly expressed in the developing heart.
important for cigarette smoking-induced IL-8 (show IL8 Antibodies) production by lung epithelial cells
CNTF (show CNTF Antibodies)(Ax15) bypasses diet-induced leptin (show LEP Antibodies) resistance to reduce hypothalamic AMPK (show PRKAA1 Antibodies) activity
CR resulted in incerasd AMPK (show PRKAA1 Antibodies) phosphorylation and, hence, activation. GHR (show GHR Antibodies) knockout animals also exhibited invrease p-AMPK (show PRKAA1 Antibodies) levels. P-AMPK (show PRKAA1 Antibodies) levels were not altered by disruption of the GHR (show GHR Antibodies) gene.
Despite high glycogen (show GYS1 Antibodies) content, the TGT400N heart is not protected against ischemia-reperfusion injury.
Ceramide- and AMPK (show PRKAA1 Antibodies)-mediated signaling pathways augment the expression and activity of 11beta-HSD1 (show HSD11B1 Antibodies) in preadipocytes by way of C/EBPbeta (show CEBPB Antibodies).
AMP-activated protein kinase (AMPK) is a heterotrimeric protein composed of a catalytic alpha subunit, a noncatalytic beta subunit, and a noncatalytic regulatory gamma subunit. Various forms of each of these subunits exist, encoded by different genes. AMPK is an important energy-sensing enzyme that monitors cellular energy status and functions by inactivating key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This gene is a member of the AMPK gamma subunit family and encodes a protein with four cystathionine beta-synthase domains. Mutations in this gene have been associated with ventricular pre-excitation (Wolff-Parkinson-White syndrome), progressive conduction system disease and cardiac hypertrophy. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
5'-AMP-activated protein kinase subunit gamma-2
, AMP-activated protein kinase gamma2 subunit
, AMPK gamma 2
, adenosine monophosphate-activated protein kinase gamma 2-subunit
, 5'-AMP-activated protein kinase gamma-2 non-catalytic subunit
, protein kinase, AMP-activated, gamma 2 non-catalytic subunit
, AMPK-activated protein kinase gamma-2 subunit
, AMPK subunit gamma-2
, 5-AMP-activated protein kinase, gamma-2 subunit
, AMPK gamma-2 chain
, AMPK gamma2